The pharmaceutical company GlaxoSmithKline has settled a health care fraud case for a record $3 billion.
The company pushed an adults-only antidepressant, Paxil, on patients under 18; promoted Wellbutrin for off-label uses such as weight loss and sexual dysfunction, and failed to provide safety data about a diabetes drug, Avanida, according to the complaint.
GSK targeted the antidepressant Paxil to patients under age 18 when it was approved for adults only, and it pushed the drug Wellbutrin for uses it was not approved for, including weight loss and treatment of sexual dysfunction, according to an investigation led by the U.S. Justice Department. The fraud included a misleading journal article and freebies for doctors that amounted to kickbacks, prosecutors said.
The states were part of the settlement. Arkansas will get $2.065 million for its Medicaid program as a result. Federal matching funds makes the payment worth $7.6 million for Medicaid. More details follow.